Fedaa Abd El-Monem Kotkata

Fedaa Abd El-Monem Kotkata

Auto-generated profile, based on publicly available information

Fedaa Abd El-Monem Kotkata

Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2021 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
TMTarek Mohamed Mostafa
Tarek Mohamed Mostafa
SHSahar Kamal Hegazy
Sahar Kamal Hegazy
SESalwa El-Morsy Abd El-Ghany
Salwa El-Morsy Abd El-Ghany
FKFedaa Abd El-Monem Kotkata
Fedaa Abd El-Monem Kotkata

1 April 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
KAKhlood Mohammad Aldossary
Khlood Mohammad Aldossary
HTHend Talkhan
Hend Talkhan
FAFurqan M Abdulelah
Furqan M Abdulelah
FKFedaa Kotkata
Fedaa Kotkata
YEYasmine M Elmorsi
Yasmine M Elmorsi
MBMostafa Bahaa
Mostafa Bahaa
Background: Non-alcoholic fatty liver disease (NAFLD) represents a prevalent, long-standing hepatic condition marked by the accumulation of fat in the liver and varying degrees of fibrotic changes. Ketotifen, a mast cell stabilizer, has been proposed to modulate inflammation and fibrogenesis, but clinical evidence is limited. Objective: To assess the effectiveness and safety of ketotifen vs vitamin E in individuals with NAFLD. The primary outcome was the change in hepatic steatosis, while the secondary outcomes included modifications in fibrosis-related indices and inflammatory biomarkers. In addition to other biochemical, anthropometric, and metabolic parameters. Methods: In this randomized study, 60 individuals with NAFLD were allocated in a 1:1 ratio into two groups. The vitamin E group was treated with vitamin E, and the ketotifen group received ketotifen for six months. Anthropometric parameters, liver steatosis and fibrosis, lipid profile, glycemic markers, liver enzymes, matrix metalloproteinase (MMP)-9, and tumor necrosis factor (TNF)-α were measured before and after 6 months. Results: Ketotifen treatment resulted in significant improvements in hepatic steatosis and disease activity compared with vitamin E, including lower steatosis and FibroScan-AST (FAST) score. Fibrosis severity was also reduced, with significant decreases in fibrosis score and fibrosis index (FIB-4) index, whereas Metabolic-Associated Steatosis Combined with Keratin-18 (MACK-3) score showed no significant between-group change. Glycemic outcomes improved significantly with ketotifen, including reductions in HOMA-IR, fasting blood glucose, and fasting insulin. Ketotifen also significantly reduced AST, TNF-α and MMP-9, and improved central adiposity measures (hip circumference, waist–stature ratio. No significant differences were observed for lipid profile, body weight, body mass index, or HbA1c. Ketotifen was generally well tolerated; drowsiness was the most common adverse event. Conclusion: Ketotifen exerts superior hepatoprotective, anti-inflammatory, antifibrotic, and insulin-sensitizing effects compared with vitamin E in NAFLD. These findings suggest that ketotifen may offer a promising adjunctive therapy for NAFLD. Clinical Trial Registration: NCT05616442.